Funding for this research was provided by:
Catabasis Pharmaceuticals (NA)
Parent Project Muscular Dystrophy (NA)
Received: 10 December 2018
Accepted: 15 April 2019
First Online: 2 May 2019
Ethics approval and consent to participate
: Written informed consent from participants or their parents/guardians was obtained in compliance with all local laws and regulations, and institutional investigational review board or ethics committee approval. The Duchenne Registry and electronic consent are approved by the Geisinger Institutional Review Board (Geisinger Medical Center, Danville, PA, IRB#2014–0621).
: Not applicable.
: LC, MM and JD are employees of Catabasis Pharmaceuticals, the study sponsor, which is developing an investigational drug, edasalonexent, for treatment of Duchenne muscular dystrophy, which is being studied in patients not on corticosteroids.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.